论文部分内容阅读
耐多药肺结核(MDR-TB)是结核病治疗中的需要应对的三大领域之一,每年新发耐多药肺结核患者12.1万例,其中初治患者为7.4万例,复治患者为4.7万例。了解耐多药结核病产生的危险因素,积极采取对肺结核患者进行形式多样的健康教育活动、进一步完善国家结核病控制策略,同时对患者进行耐药监测,三方面工作进行耐多药结核病的预防和治疗。来达到减少耐多药结核病的人群数量,降低影响提高预防和治疗措施。
Multidrug-resistant tuberculosis (MDR-TB) is one of the three major areas that need to be addressed in the treatment of tuberculosis. Each year, 121,000 MDR-TB patients are newly diagnosed, of whom 74,000 are newly diagnosed and 47,000 are retreated example. To understand the risk factors for MDR-TB and actively take various forms of health education activities for patients with tuberculosis, to further improve the national tuberculosis control strategy, to monitor the drug resistance of patients and to carry out MDR-TB prevention and treatment in three aspects . To reduce the number of people with MDR-TB and to reduce their impact and improve their prevention and treatment measures.